相关临床试验
37
1 进行中
药物批准
154
批准总数
监管机构
1
监管机构数
成立时间
N/A
已完成
30
81.1%
尚未招募
1
2.7%
终止
1
2.7%
撤回
5
13.5%
- Wockhardt filed a Marketing Authorisation Application with the European Medicines Agency on January 5, 2026, for WCK 5222, a novel antibiotic combining Zidebactam and Cefepime to treat resistant Gram-negative infections. - The European Medicines Agency granted WCK 5222 Accelerated Assessment status, recognizing its potential to address unmet medical needs in treating multidrug-resistant and extremely drug-resistant Gram-negative pathogens. - WCK 5222 represents a landmark achievement as the first New Chemical Entity discovered and developed in India to be submitted for pan-European marketing authorisation. - The drug is designed to treat serious infections including complicated urinary tract infections, hospital-acquired pneumonia, and complicated intra-abdominal infections caused by resistant bacteria.
- The US FDA has formally accepted Wockhardt's New Drug Application for Zaynich, making it the first New Chemical Entity from an Indian pharmaceutical company to achieve this milestone. - Zaynich is a novel β-lactam enhancer mechanism-based antibiotic with Fast Track designation, designed to combat highly resistant Gram-negative pathogens that cause severe infections and high mortality rates. - The antibiotic has demonstrated life-saving potential through compassionate use in critically ill patients in both India and the US, following over a decade of development since 2011. - The FDA acceptance triggered a 19% surge in Wockhardt shares on December 1, 2025, though the stock experienced subsequent volatility with profit-taking in following sessions.
- Wockhardt's stock price jumped 19% after the US FDA accepted the company's New Drug Application for Zaynich, an antibiotic treatment. - The FDA acceptance represents a significant regulatory milestone for Wockhardt's antibiotic development program. - This development marks an important step forward in the company's efforts to bring new antimicrobial therapies to market.
- India has developed its first indigenously discovered antibiotic, Nafithromycin, through collaboration between the Department of Biotechnology and Wockhardt pharmaceutical company. - The antibiotic demonstrates effectiveness against resistant respiratory infections, particularly benefiting cancer patients and individuals with poorly controlled diabetes. - India achieved a breakthrough in gene therapy with the first successful indigenous clinical trial for Hemophilia treatment, showing 60-70% correction rate with zero bleeding episodes. - The country has sequenced over 10,000 human genomes and aims to scale up to one million genomes as part of its national genomic mission.
- Wockhardt has submitted a New Drug Application to the US FDA for Zidebactam-Cefepime injection, marking the first NDA submission for a drug fully discovered and developed by an Indian pharmaceutical company. - The novel antibacterial agent targets complicated urinary tract infections caused by multidrug-resistant Gram-negative bacteria, addressing a significant global health burden with over 8 million cases reported annually in the US and EU. - The submission follows successful completion of a pivotal Phase III global clinical trial conducted across 64 sites in nine countries, with the drug demonstrating efficacy against carbapenem-resistant infections. - Zidebactam-Cefepime represents a first-in-class β-lactam enhancer combination with a novel mechanism of action to combat difficult-to-treat infections that remain unresponsive to currently approved antibiotics.
- The FDA quietly permitted more than 150 exempted products from officially banned foreign factories to continue shipping to the United States for over a dozen years to prevent drug shortages. - ProPublica's investigation revealed that most exempted drugs came from factories in India, with additional facilities in China and Hungary, despite dangerous manufacturing failures that led to import bans. - The agency did not regularly test these exempted drugs or proactively monitor safety reports describing products with foul odors, abnormal taste, or consumers experiencing unexplained health problems. - Several factories remain banned but continue receiving exemptions, while the FDA kept this practice largely hidden from the public without releasing a comprehensive list until now.
- Wockhardt Ltd has filed for voluntary liquidation of its US subsidiaries Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC under Chapter 7 of the US Bankruptcy Code to exit its loss-making generics business. - The company's US generics business incurred nearly $8 million in losses in FY25 and has been unprofitable for several years, prompting the strategic exit. - Wockhardt is pivoting to focus on its novel antibiotic drug discovery program, with six candidates in development targeting drug-resistant bacterial infections. - The company's lead antibiotic candidate Zaynich has completed global phase 3 trials and has an addressable market potential of $7 billion in the US and Europe.
- India launches the ₹5,000 crore Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme, expected to attract ₹17,000 crore in additional R&D investment by end of 2025. - The initiative comes as 24 mega-selling drugs worth over $250 billion in combined annual sales will lose patent protection by 2030, creating unprecedented opportunities for Indian generic manufacturers. - Indian pharmaceutical companies including Zydus, Sun Pharma, and Bharat Serums are investing heavily in world-class R&D centers to develop new chemical entities and transition from generic-focused to innovation-driven operations. - The sector has grown dramatically from $8 billion in 2005-06 to $50 billion in 2023-24, with India now ranking as the world's third largest pharmaceutical producer by volume.
- Senores Pharmaceuticals has acquired the US FDA-approved ANDA for enalapril maleate tablets in multiple dosages from Wockhardt, expanding its presence in the hypertension treatment market. - The US market for enalapril tablets is valued at $28.60 million (MAT December 2024) according to IQVIA data, representing a significant commercial opportunity for Senores. - With this acquisition, Senores strengthens its portfolio to 61 ANDAs and 22 CMO/CDMO commercial products approved for distribution in the United States.
- DelveInsight's 2025 pipeline analysis reveals 12+ pharmaceutical companies actively developing therapies for complicated urinary tract infections, with several candidates in advanced clinical stages. - Spero Therapeutics' tebipenem pivoxil hydrobromide completed a landmark Phase III trial (ADAPT-PO) demonstrating non-inferiority to IV ertapenem, potentially becoming the first oral carbapenem approved in the United States. - Recent regulatory approvals include GSK's Blujepa (gepotidacin) for uncomplicated UTIs and AbbVie's EMBLAVEO for complicated intra-abdominal infections, highlighting growing treatment options. - Multiple Phase III studies are underway in 2025, including pediatric trials by Menarini Group and Rempex evaluating meropenem-vaborbactam combinations for hospitalized patients.
